Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04022616

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Ability to give informed consent
  • Stage I-III breast malignancy

Exclusion criteria

  • Unable to tolerate venipuncture

Treatment and study plan

Specimen Collection

Other

Specimens are obtained from patients who are being treated for breast malignancies.

Primary outcomes

  1. Isolate unfavorable immune cells MDSC from the peripheral blood or tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells.

    Time frame: up to 1 year

    Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.

    isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood or the tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells. Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.

Secondary outcomes

  1. Isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood of study subjects who plan to start pre-operative chemotherapy for breast cancer to see if MDSC levels can predict who will respond to treatment. W

    Time frame: up to 1 year

    Percentage of MDSC at baseline and whether there is an association of baseline MDSC percent with response to chemotherapy.

  2. Isolate unfavorable immune cells MDSC from peripheral blood of study subjects who receive pre-operative chemotherapy for breast cancer to identify changes in MDSC levels during treatment can predict who will respond to treatment.

    Time frame: up to 1 year

    Changes will be reported in percentage of MDSC and associations of such changes with response to chemotherapy.

  3. Isolate lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present.

    Time frame: up to 1 year

    Isolate a lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present. Natural Killer cells are immune cells that are capable of killing cancer cells.

Study contacts

Contact information is provided by the study sponsor or research team.

Ohio State Comprehensive Cancer Center

CONTACT

[email protected]

1-800-293-5066

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Registry information

Important dates

Study start
2010
Primary completion
2027
Study completion
2027
First posted
Jul 17, 2019
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.